Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution.

Next Previous
Trial Profile

CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agatolimod (Primary)
  • Indications Acute myeloid leukaemia; Germ cell and embryonal neoplasms; Germ cell cancer; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 19 May 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 19 May 2010 Planned number of patients changed from 25 to 16 as reported by ClinicalTrials.gov.
  • 19 May 2010 Planned end date changed from 1 Aug 2008 to 1 May 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top